Ophthalmic Drugs Market Size, Share Global Analysis Report, 2021 - 2026

Industry Insights

[197+ Pages Report] We at Facts & Factors have recently published a report titled “Global Ophthalmic Drugs Market” that encompasses the spectacle of the market in an analytical and comprehensive manner. In this study, the global ophthalmic drugs market is projected to value USD 62.9 Billion in the year 2026 from an initial value of USD 37.4 Billion in the year 2020 growing at a CAGR value of 5.9%.

Market Overview

Ophthalmic is a branch of medicine and surgery that deals with the diagnosis and treatment of disorders relating to the eye. Professional service providers for the ophthalmic sector are known ophthalmologist and their credentials include a degree in medicine followed by five years of residency training of on-site. They often prescribe medications for treating eye disorders, implementing laser therapy measures, and performing surgeries whenever needed.

Industry Growth Factors

The primary driving factors for the significant growth of the global ophthalmic drugs market during the advent of the forecast period are the rising prevalence of eye-related disorders such as presbyopia, macular degeneration, and diabetic retinopathy among the aging population coupled with the increasing introduction of ophthalmic devices equipped with advanced technologies to name a few. Additionally, the rising need for ophthalmic surgeries coupled with rising collaborations between the key market players will increase the footprint of the global ophthalmic drugs market during the forecast period. Moreover, rising instances of gene therapy for treating hereditary ophthalmic diseases coupled with an increase in the geriatric population will boost the growth of the global ophthalmic drugs market during the forecast period.

The global ophthalmic drugs market is driven by rising investments in R&D activities coupled with increasing initiatives undertaken by various government initiatives to name a few. Additionally, the surging demand for ophthalmic drugs coupled with rising instances of cataract, glaucoma, color blindness, diabetic macular edema, and CMV retinitis, to name a few. However, a lack of health coverage measures coupled with low consumer awareness about the wider range of ophthalmic diseases will decrease the market share of the global ophthalmic drugs market during the forecast period.

Segmentation Analysis

The global ophthalmic drugs market is segmented into drug class, disease type, dosage, route of administration, product, and region.

The global ophthalmic drugs market is divided into anti-allergy, anti-VEGF agents, anti-inflammatory, antiglaucoma, and others on the basis of drug class. The segment pertaining to anti-VEGF (vascular endothelial growth factors) is expected to witness the largest market share during the advent of the forecast period owing to strong commercial performances of the drug class coupled with the rising number of undergoing clinical studies for developing anti-inflammatory eye disorders to name a few. The global ophthalmic drugs market is categorized into the dry eye, eye allergy, glaucoma, eye infection, retinal disorders, uveitis, and others on the basis of disease. The segment pertaining to retinal disorders is expected to witness the largest market share during the advent of the forecast period owing to the presence of a stronger pipeline of products and increasing volumes coupled with rising cases of COVID-19 and COVID-19 related eye disorders to name a few.

Based on dosage, the global ophthalmic drugs market is fragmented into gels, eye solutions, capsules & tablets, eye drops, and ointments. The eye drops category is expected to witness the largest market share during the advent of the forecast period owing to ease of usage, higher patient compliance rate coupled with a lower and devastating impact for the treatment of eye disorders to name a few. The global ophthalmic drugs market is classified into topical, local ocular, and systematic on the basis of route of administration. The segment pertaining to topical is expected to occupy the largest market share during the advent of the forecast period owing to rising product launches of new products coupled with rising sales volumes in terms of retinal disorders to name a few. The global ophthalmic drugs market is bifurcated into prescription drugs and OTC on the basis of product. The segment pertaining to prescription drugs is expected to witness the largest market share during the advent of the forecast period owing to improving safety and efficacy profiles coupled with a lower price point to name a few.

Report Scope

Regional Analysis

North America is expected to witness the largest market share during the advent of the forecast period owing to the presence of a well-established healthcare infrastructure coupled with a higher rate of consumer awareness due to early adoption of the technology to name a few. Additionally, the presence of key market players in the region coupled with the rising number of middle-class households will increase the footprint of the ophthalmic drugs market during the forecast period. Asia-Pacific is expected to witness the fastest growing CAGR during the forecast period owing to a risen burden of ophthalmic disorders coupled with an increasing number of local and regional efforts to provide better quality products to name a few. Moreover, improving medical infrastructure coupled with the rising penetration of health insurance solutions will further push the existing boundaries of the ophthalmic drugs market in the region toward a higher growth share.

Competitive Players

The key market participants for the global ophthalmic drugs market are

• Alcon
• Johnson & Johnson Services Inc.
• Bausch Health
• Allergan
• Pfizer Inc.
• Bayer AG
• Santen Pharmaceutical Co. Ltd.
• Genetech Inc.
• Novartis AG
• Regeneron
• Merck & Co.
• Coherus Biosciences Inc.
• AbbVie Inc.
• F. Hoffmann-La Roche Ltd.
• Teva Pharmaceutical Industries Ltd.
• Sun Pharmaceutical Industries Ltd.

By Drug Class Segment Analysis

• Antiallergy
• Anti-VEGF Agents
• Anti-Inflammatory
  • Nonsteroidal Drugs
  • Steroidal Drugs
• Antiglaucoma
• Others

By Disease Segment Analysis

• Dry Eye
• Eye Allergy
• Glaucoma
• Eye Infection
• Retinal Disorders
  • Macular Degeneration
  • Diabetic Retinopathy
  • Others
• Uveitis
• Others

By Dosage Segment Analysis

• Gels
• Eye Solutions
• Capsules & Tablets
• Eye Drops
• Ointments

By Route of Administration Segment Analysis

• Topical
• Local Ocular
  • Subconjunctival
  • Retrobulbar
  • Intracameral
• Systematic

By Product Segment Analysis

• Prescription Drugs
• OTC

By Regional Segment Analysis

• North America
  • U.S.
  • Canada
• Europe
  • UK
  • France
  • Germany
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • GCC Countries
  • South Africa
  • Rest of MEA